Improved monitoring of ovarian stimulation using 3D transvaginal ultrasound plus automated volume count
Abstract
Two-dimensional transvaginal ultrasound (2D) is typically performed to monitor follicle growth in IVF and to determine the optimal time for administering human chorionic gonadotrophin. However, 2D only provides an approximation of the real volume of follicles and therefore cannot be used to guarantee standards for follicular measurement. The automated measurement of follicular size in three dimensions (3D) using a software programme that identifies and quantifies hypoechoic regions within a 3D dataset might provide an objective, fast, valid and reliable standard for such measurements. A prospective controlled study (group I: 20 patients, 2D; group II: 20 patients, 3D) investigated how the criteria for triggering oocyte maturation that are normally used in 2D compare to the new and more accurate method of measuring follicles using 3D-based automated volume count. Significantly more oocytes were fertilized (group 1: 7.1
±
4.5, group 2: 11.5
±
6.4; P
<
0.03) when using 3D technology and automated volume count. The study assumes that the automated volume count more closely mirrors the biological reality, which means that it can also be used to guarantee the quality standards established by the European Union directive on tissues and cells (2004/23/EC). This new technology therefore holds great promise of becoming the new standard for monitoring follicular growth in IVF.
Keywords: automated volume count, in-vitro fertilization, monitoring, ovarian stimulation, three-dimensional ultrasound
To access this article, please choose from the options below
Dr Maximilian Murtinger received his MD at the University of Vienna in 1986. After specialization as a trauma surgeon in 2003, he changed to the field of reproductive medicine and endocrinology and is currently finishing his specialization in obstetrics and gynecology. His current interest is in ultrasound techniques, especially related to follicular measurements in stimulated cycles and in establishing clinical standards related to the quality criteria set by the European Union directive on tissues and cells (2004/23/EC). In addition, Dr Murtinger is developing requirements for software used in obstetrics and gynecology, especially for reproductive medicine and endocrinology.Dr Maximilian Murtinger
PII: S1472-6483(09)00072-8
doi:10.1016/j.rbmo.2009.09.008
© 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK. Published by Elsevier Inc. All rights reserved.
